Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00632970 · ClinicalTrials.gov registry record · Phase 4
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals
A Phase 4 study, sponsored by George Washington University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT00632970 is a Phase 4 study that was terminated before completion, run by George Washington University. The registered enrollment target is 6 participants.
The verdict
NCT00632970, a Phase 4 study, was terminated before completion, sponsored by George Washington University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada.
Interventions
- DRUG Truvada
- DRUG Lopinavir/Ritonavir
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00632970
The ClinicalTrials.gov registry entry for NCT00632970 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Truvada is the first listed.
NCT00632970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00632970 about?
NCT00632970 is a clinical study titled "Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals". This program is designed to study the efficacy, safety, lipid effects and tolerability of raltegravir compared to lopinavir/ritonavir, in patients with HIV-I infection who have not received prior antiretroviral therapy. All patients will receive concomitant therapy with Truvada.
What is the current status of trial NCT00632970?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2008-02. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00632970?
The interventions under investigation include: Truvada (DRUG), Lopinavir/Ritonavir (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00632970?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.